Cairo university hospitals, dermatology outpatient clinic
Cairo, Egypt
NCT Number: NCT03622320
This study aims at detection of possible associated metabolic syndrome with vitiligo and assessment of possible contribution of the age of onset of vitiligo.
Looking for future studies?
Notify MeAll sexes
Observational
Cairo, Egypt
This study aims at detection of incidence of metabolic syndrome in vitiligo patients and possible contribution of the age of onset of the disease. This involves detection of waist circumference, body mass index, index of central obesity, systolic and diastolic arterial blood pressure, fasting blood sugar, high density lipoproteins and triglycerides, in addition to insulin resistance as Homeostatic Model Assessment- insulin resisitance (HOMA-IR) and serum leptin in vitiligo patients. The outcomes will be correlated to extent/ severity/duration/ activity of vitiligo as well as to the age of onset. This is assumed to be of profound impact on vitiligo patients by properly assessing these patients for associated metabolic risk factors and helping prevent such metabolic derangements by detection of possible contributing factors such as insulin resistance and high serum adipokines as leptin.
Since there is temporal relation between nutrition, metabolic derangements and skin diseases where nutritional deficiencies as minerals, vitamins and fatty acids can lead to cutaneous manifestations and , on the other hand; skin diseases could contribute to metabolic derangements and nutritional deficiencies, the investigator's study will focus on nutrition and dietary habits and there possible contribution to any associated metabolic risk in vitiligo patients.
This is likely to open new horizons in the management of vitiligo, possibly through control of metabolic syndrome risk factors and insulin resistance as well as revealing possible temporal relation to dietary habits that are overlooked in vitiligo patients.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin
Time frame: one year
Central obesity will be assessed using waist circumference in cm in vitiligo patients and control group as a risk factor for metabolic syndrome
Time frame: one year
Arterial Blood Pressure will be assessed in vitiligo patients and control group as a risk factor for metabolic syndrome
Time frame: one year
Fasting Blood pressure will be assessed in vitiligo patients and control group as a risk factor for metabolic syndrome
Time frame: one year
Serum Triglycerides and HDL will be assessed in vitiligo patients and control group as a risk factor for metabolic syndrome
Time frame: one year
Body Mass index in kg/m2 will be assessed in vitiligo patients and control group as a risk factor for metabolic syndrome
Time frame: one year
This is via measuring HOMA-IR
Time frame: one year
This via detecting VASI, VES and VIDA scores for vitiligo patients
Time frame: one year
This via detecting VASI, VES and VIDA scores for vitiligo patients and relating to the age of onset
Time frame: one year
This via directly addressing dietary habits
Cairo University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07702669
Glucose Metabolism Disorders, Hyperinsulinism
Harbin, Heilongjiang, China
View Trial DetailsNCT06186102
Arterial Occlusive Diseases, Arteriosclerosis
Aarhus, Jutland, Denmark
View Trial DetailsNCT06268990
Body Weight, Diabetes
Graz, Austria
View Trial DetailsNCT07616570
Arachnodactyly, Congenital Abnormalities
Istanbul, Turkey (Türkiye)
View Trial Details